Key Highlights
- 4.13% is the indicated pre-market gain for Onconetix, Inc. (NASDAQ:ONCO) on November 19, 2026, taking the indicated price to USD 3.15 from a calculated prior close of USD 3.02 on only 2,178 shares.
- 1-for-10 Reverse Stock Split took effect at 12:01 a.m. ET on November 6, 2026, cutting outstanding common stock from about 6.7 million shares to about 670,000 shares under the company filing.
- 2 sources of strain stand out: USD 2.7 million of cash at September 30, 2026 compares with nine-month operating cash use of USD 5.8 million, and management says substantial doubt about Going Concern is not alleviated.
- 75% to 95% of Fully Diluted Shares would go to the Realbotix seller under an amended deal now due by March 31, 2027, with USD 3 million already advanced to Realbotix under an unsecured note.
What Moved Onconetix, Inc. (NASDAQ:ONCO) in Pre-Market Trading on November 19, 2026 (+USD 0.13, +4.13%)
The indicated pre-market price for Onconetix, Inc. (NASDAQ:ONCO) is USD 3.15, a pre-market move of +4.13% on November 19, 2026, before the 9:30 a.m. ET open. The calculated prior close is USD 3.02 (price divided by 1.0413) and the calculated USD move is +USD 0.13. Pre-market Volume is only 2,178 shares, so the indication rests on very thin trading. Using about 670,000 shares, the calculated market Capitalization is roughly USD 2.11 million.
The Rationale: No Fresh Catalyst Identified, Reverse Split and Realbotix Context for Onconetix, Inc. (NASDAQ:ONCO)
No catalyst was identified in published coverage for this morning's indication. As general context, a stock that completed a reverse split on November 6, 2026 trades on a much smaller share base, and low-priced, thinly traded small-caps can move sharply on a handful of trades. A November 4, 2026 amendment extended the Realbotix transaction deadline to March 31, 2027, and the company has advanced USD 3 million under an unsecured note, with up to USD 2 million more available.
Valuation, Liquidity and Risks for Onconetix, Inc. (NASDAQ:ONCO)
Small-cap warning: a calculated market capitalization near USD 2.11 million places the company well under USD 100 million, so Volatility and dilution risk are high. Nine-month Revenue was about USD 140,000, made up of USD 100,000 from Immunovia materials and USD 40,000 from Proclarix. A USD 30.4 million noncash commitment fee was tied to Series F shares issued for a July Equity line with a USD 750 million ceiling, subject to a 19.99% share cap. That line had produced no proceeds through September 30, 2026.
Where Things Stand
Onconetix, Inc. (NASDAQ:ONCO) is indicated at USD 3.15 pre-market on November 19, 2026, up USD 0.13 (calculated) or 4.13% from a calculated prior close of USD 3.02, with pre-market volume of 2,178 shares. The latest reported period is the third quarter ended September 30, 2026, which showed cash of USD 2.7 million, nine-month operating cash use of USD 5.8 million and unresolved substantial doubt about continuing as a going concern. The company completed a 1-for-10 reverse split on November 6, 2026 and continues to trade on The Nasdaq Capital Market. Further dilution, financing needs and the Realbotix outcome remain the central risks.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...